← All trials
NCT05848102
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 23, 2022
- Primary completion
- Oct 23, 2024
- Completion date
- Apr 23, 2025
- First posted
- May 8, 2023
- Last posted
- May 8, 2023
- Enrollment
- 166
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Sun Yat-Sen UniversityLead sponsor
- Guangdong Medical UniversityCollaborator
- Sun Yat-Sen UniversityCollaborator
- Sun Yat-Sen UniversityOverall official - principal investigator
- Jieyang People's HospitalCollaborator
- Guangzhou Medical UniversityCollaborator
- Sun Yat-Sen UniversityReponsible party - principal investigator
- Sun Yat-Sen UniversityCollaborator
- Yuebei People's HospitalCollaborator
- Xiamen UniversityCollaborator
- Sun Yat-Sen UniversitySponsor investigator
- Sun Yat-Sen UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.